MICROALBUMINURIA - PROGNOSTIC AND THERAPEUTIC IMPLICATIONS IN DIABETES-MELLITUS

被引：49

作者：

GILBERT, RE

COOPER, ME

MCNALLY, PG

OBRIEN, RC

TAFT, J

JERUMS, G

机构：

[1] Endocrinology Unit, Austin Hospital, Heidelberg

[2] Department of Medicine, Heidelberg Repatriation Hospital, Heidelberg

[3] Department of Medicine, Monash Medical Centre, Clayton

[4] Department of Endocrinology, Royal Melbourne Hospital, Parkville, Victoria

来源：

DIABETIC MEDICINE | 1994年 / 11卷 / 07期

关键词：

TYPE-1; DIABETES; TYPE-2; NEPHROPATHY; CARDIOVASCULAR DISEASE; ANTIHYPERTENSIVE THERAPY; MICROALBUMINURIA;

D O I：

10.1111/j.1464-5491.1994.tb00325.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Thirty years following the development of the first radioimmunoassay for albumin, microalbuminuria is widely acknowledged as an important predictor of overt nephropathy in patients with Type 1 diabetes and of cardiovascular mortality in Type 2 diabetes. In addition, there is accumulating evidence to suggest that diabetic patients with microalbuminuria may have more advanced retinopathy, higher blood pressure, and worse dyslipidaemia than patients with normal albumin excretion rates. Recent studies have focused on the role of intervention, principally with antihypertensive therapy and intensive glycaemic control, in reducing microalbuminuria. While successful in reducing urinary albumin excretion it remains to be established whether such therapies will be translated into a reduction in renal failure and decreased cardiovascular mobidity and mortality.

引用

页码：636 / 645

页数：10

共 126 条

[1]

Sepe SJ, Teutsch SM, Epidemiology of renal involvement in diabetes mellitus, The Kidney and Hypertension in Diabetes., pp. 17-23, (1988)

[2]

Disney APS, Fifteenth Annual Report of the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA)., (1992)

[3]

Challah S., Brunner FP, Wing AJ, Evolution of the treatment of patients with diabetic nephropathy by renal replacement therapy in Europe over a decade: data from the EDTA registry, The Kidney and Hypertension in Diabetes., pp. 365-377, (1988)

[4]

Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR, The changing natural history of nephropathy in type I diabetes, Am J Med, 78, pp. 785-794, (1985)

[5]

Cameron SJ, Challah S., Treatment of end‐stage renal failure due to diabetes in the United Kingdom, 1975‐1984, Lancet, 2, pp. 962-966, (1986)

[6]

Mogensen CE, Christensen CK, Predicting diabetic nephropathy in insulin‐dependent diabetic patients, N Eng J Med, 311, pp. 89-93, (1984)

[7]

Mogensen CE, Microalbuminuria predicts clinical pro‐teinuria and early mortality in maturity‐onset diabetes, N Eng J Med, 310, (1984)

[8]

Tiu SC, Lee SS, Cheng MW, Comparison of six commercial techniques in the measurement of microalbuminuria in diabetic patients, Diabetes Care, 16, pp. 616-620, (1993)

[9]

Keen H., Chlouverakis C., An immunoassay method for urinary albumin at low concentrations, Lancet, 2, pp. 913-914, (1963)

[10]

Viberti GC, Wiseman M., The kidney in diabetes: significance of early abnormalities, Clin Endocrinol Metab, 15, pp. 753-782, (1986)

← 1 2 3 4 5 6 7 8 9 10 →